About IMB Dx
IMB Dx is a publicly listed company based in Seoul (South Korea) founded in 2018. In-vitro diagnostic kits for blood cancer are developed. The company has 58 employees. Its chief executive, as recorded, is Peter Moon. Its website imbdx.com draws about 22 thousand monthly visits. IMB Dx offers products and services including AlphaLiquid®, CancerDetect™, and CancerFind™. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Blood Cancer. Its legal entity is IMBdx Inc.
Company details
IMB Dx was founded in 2018 in Seoul, South Korea. Operations focus on the biotechnology sector, where in-vitro diagnostic kits for cancer are created. Trace amounts of cancer-derived genes in blood samples are detected through these kits. Early diagnosis for ongoing patients is supported, along with monitoring for recurrence risks following cancer surgery. The domain imbdx.com is utilized for online presence.
- Annual Revenue$3.69 M (USD)56.4as on Dec 31, 2025
- Net Profit-$5.49 M (USD)17.15as on Dec 31, 2025
- EBITDA-$5.01 M (USD)19.64as on Dec 31, 2025
- Employee Count58
Products & Services of IMB Dx
IMB Dx offers a comprehensive portfolio of products and services, including AlphaLiquid®, CancerDetect™, and CancerFind™.
AI-driven tool for cancer monitoring and profiling in patients.
Service for early detection of cancer recurrence post-treatment.
Blood-based test for screening multiple cancer types efficiently.
Apps and channels of IMB Dx
its YouTube channel IMBdx has 106 subscribers and 11 videos.
Videos from IMB Dx
The most watched videos on IMB Dx's YouTube channel, IMBdx (106 subscribers). Click a video to play it here.
More on IMBdx.
People of IMB Dx
1 people are tracked at IMB Dx (1 in leadership); the tracked headcount is 58.
| Name | Role | Group |
|---|---|---|
Peter Moon | CEO | Leadership |
Complete people profiles for IMB Dx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of IMB Dx
IMB Dx is a publicly listed company on the KRX with ticker symbol 461030 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Apr 2024
- Listed onKRX: 461030
- Listed entityIMBdx, Inc.
- Exchange sectorHealth technology
- ISINKR7461030009
- Share price2,665.00 KRW (-1.3% on the day) · 2026-10-14
- Market capitalisation38,703,194,618.00 KRW
- EPS (diluted, trailing year)-538.51 KRW
- Volume (last session)11,912
Financials of IMB Dx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 5.33B KRW | -7.93B KRW | -7.23B KRW |
| 2024 | 3.41B KRW | -9.58B KRW | -9.00B KRW |
| 2023 | 4.03B KRW | -10.42B KRW | -6.12B KRW |
| 2022 | 2.62B KRW | -10.44B KRW | -7.17B KRW |
| 2021 | 1.23B KRW | -9.79B KRW | -4.31B KRW |
Detailed financial statements for IMB Dx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of IMB Dx
The website of IMB Dx (imbdx.com) receives about 22.1K visits a month.
- Monthly visits22.1K
▲ 16.3% vs previous month
Websites whose visitors overlap most with IMB Dx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cbnuh.or.kr | 100% | 680.7K | #182,994 | View details | |
drh.co.kr | drh.co.kr | 91% | #717,577 | – | |
kumc.or.kr | kumc.or.kr | 88% | #113,938 | – | |
mjh.or.kr | mjh.or.kr | 85% | #203,738 | – | |
kimjinmok.com | kimjinmok.com | 85% | #5,493,462 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for IMB Dx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Imb Dx
Complete news archive for IMB Dx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IMB Dx
IMB Dx was founded in 2018.
IMB Dx is headquartered in Seoul, South Korea.
Peter Moon is the CEO of IMB Dx, as recorded in our data.
IMB Dx has 58 employees.
Annual revenue of IMB Dx is $3.69M as on Dec 31, 2025.
IMB Dx was founded in 2018 in Seoul, South Korea. Operations focus on the biotechnology sector, where in-vitro diagnostic kits for cancer are created. Trace amounts of cancer-derived genes in blood samples are detected through these kits. Early diagnosis for ongoing patients is supported, along with monitoring for recurrence risks following cancer surgery. The domain imbdx.com is utilized for online presence.
IMB Dx offers AlphaLiquid®, CancerDetect™, and CancerFind™.
Yes, IMB Dx is publicly traded on KRX under the ticker symbol 461030.
IMB Dx operates through Imbdx Inc.